Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.53 |
| ▸ | CCR5 | P51681 | 5/20 | 0.50 |
| ▸ | RAB9A | P51151 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | USP28 | Q96RU2 | 1/20 | 0.49 |
| ▸ | USP25 | Q9UHP3 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 3/20 | 0.48 |
| ▸ | KDM1A | O60341 | 2/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 1/20 | 0.47 |
| ▸ | LTA4H | P09960 | 1/20 | 0.47 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.47 |
| ▸ | F9 | P00740 | 1/20 | 0.46 |
| ▸ | F10 | P00742 | 1/20 | 0.46 |
| ▸ | PTGER1 | P34995 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3713861 | 0.86 | CCR5 (0.54) | SLC6A4MAOBCCR5RAB9AALDH1A1 | |
| SCHEMBL368071 | 0.84 | SLC6A4 (0.66) | SLC6A4MAOBCCR5RAB9AALDH1A1 | |
| SCHEMBL31644088 | 0.84 | SLC6A4 (0.66) | SLC6A4MAOBCCR5RAB9AALDH1A1 | |
| SCHEMBL24133495 | 0.83 | MAOB (0.54) | MAOBCCR5RAB9AHTTSMN1; SMN2 | |
| SCHEMBL30026191 | 0.83 | MAOB (0.50) | SLC6A4MAOBCCR5RAB9AALDH1A1 | |
| SCHEMBL22412158 | 0.83 | MAOB (0.50) | SLC6A4MAOBCCR5RAB9AALDH1A1 | |
| SCHEMBL30461784 | 0.83 | MAOB (0.50) | SLC6A4MAOBCCR5RAB9AALDH1A1 | |
| SCHEMBL22412255 | 0.83 | MAOB (0.50) | SLC6A4MAOBCCR5RAB9AALDH1A1 | |
| SCHEMBL8298067 | 0.82 | MAOB (0.56) | MAOBRAB9ASMN1; SMN2APPLTA4H | |
| SCHEMBL4434864 | 0.82 | SLC6A4 (0.56) | SLC6A4MAOBCCR5RAB9AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3573972-B1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2026-01-14 | — | — | EP | disclosed |
| CN-116947678-A | Nitrogen-atom-disubstituted aromatic ring micromolecular organic compound, derivatives thereof and application of nitrogen-atom-disubstituted aromatic ring micromolecular organic compound in preparation of antibacterial drugs | 河南大学 | 2023-10-27 | — | — | CN | disclosed |
| US-11077115-B2 | Rorgamma modulators and uses thereof | GENFIT (FR) | 2021-08-03 | — | — | US | disclosed |
| US-11077115-B2 | Rorgamma modulators and uses thereof | GENFIT (FR) | 2021-08-03 | — | — | US | disclosed |
| WO-2018138359-A1 | RORGAMMA MODULATORS AND USES THEREOF | GENFIT (FR) | 2018-08-02 | — | — | WO | disclosed |
| US-8575186-B2 | Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof | ALBANY MOLECULAR RESEARCH, INC. (US) | 2013-11-05 | — | — | US | disclosed |
| US-20110112122-A1 | EPIMINOCYCLOALKYL[b] INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-05-12 | — | — | US | disclosed |
| WO-2011044134-A1 | EPIMINOCYCLOALKYL(B)INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS AND USES THEREOF | ALBANY MOLECULAR RESEARCH, INC. (US) | 2011-04-14 | — | — | WO | disclosed |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NEURO3D (FR) | 2006-08-17 | — | — | US | disclosed |
| EP-1451159-A1 | COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF | NEURO3D (FR) | 2004-09-01 | — | — | EP | disclosed |
| WO-2003010146-A1 | COMPOSITIONS DERIVED FROM QUINOLINE AND QUINOXALINE, PREPARATION AND USE THEREOF | NEURO3D (FR) | 2003-02-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110112122-A1 | EPIMINOCYCLOALKYL[b] INDOLE DERIVATIVES AS SEROTONIN SUB-TYPE 6 (5-HT6) MODULATORS AND USES THEREOF | HTR6, HTR3B, HTR1B | SLC6A4 21/4885MAOB 27/4885CCR5 848/4885 |
| US-20060183909-A1 | Compositions derived from quinoline and quinoxaline, preparation and use thereof | NQO1, NQO2, RECQL | SLC6A4 1611/4885MAOB 402/4885CCR5 889/4885 |
| US-11077115-B2 | Rorgamma modulators and uses thereof | RORB, RORC, RORA | SLC6A4 4855/4885MAOB 4088/4885CCR5 268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.